NCT04600687View on ClinicalTrials.gov

B/F/TAF Ease of Swallowability Trial

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 6, 2018

Primary Completion Date

May 8, 2019

Study Completion Date

October 10, 2020

Conditions
HIV Infections
Interventions
OTHER

Placebo tablets

Participants will take placebo tablets identical to the commercial versions of the two combination antiretroviral single tablet regimens of bictegravir/emtricitabine/tenofovir alanfenamide and dolutegravir/abacavir/lamivudine.

Trial Locations (1)

48202

John McKinnon, Detroit

All Listed Sponsors
lead

Henry Ford Health System

OTHER

NCT04600687 - B/F/TAF Ease of Swallowability Trial | Biotech Hunter | Biotech Hunter